BCR and non-small cell lung carcinoma: Noteworthy examples include imatinib, which inhibits the BCR/ABL tyrosine kinase in chronic myeloid leukemia (CML), and gefitinib, targeting the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC).